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Recent advances in neuroimaging data acquisition and analysis hold the promise to 
enhance the ability to make diagnostic and prognostic predictions and perform treat-
ment planning in neuropsychiatric disorders. Prior research using a variety of types of 
neuroimaging techniques has confirmed that neuropsychiatric disorders are associated 
with dysfunction in anatomical and functional brain circuits. We first discuss current chal-
lenges associated with the identification of reliable neuroimaging markers for diagnosis 
and prognosis in mood disorders and for neurosurgical treatment planning for deep brain 
stimulation (DBS). We then present data on the use of neuroimaging for the diagnosis 
and prognosis of mood disorders and for DBS treatment planning. We demonstrate 
how multivariate analyses of functional activation and connectivity parameters can be 
used to differentiate patients with bipolar disorder from those with major depressive 
disorder and non-affective psychosis. We also present data on connectivity parameters 
that mediate acute treatment response in affective and non-affective psychosis. We then 
focus on precision mapping of functional connectivity in native space. We describe the 
benefits of integrating anatomical fiber reconstruction with brain functional parameters 
and cortical surface measures to derive anatomically informed connectivity metrics within 
the morphological context of each individual brain. We discuss how this approach may 
be particularly promising in psychiatry, given the clinical and etiological heterogeneity of 
the disorders, and particularly in treatment response prediction and planning. Precision 
mapping of connectivity is essential for DBS. In DBS, treatment electrodes are inserted 
into positions near key gray matter nodes within the circuits considered relevant to 
disease expression. However, targeting white matter tracts that underpin connectivity 
within these circuits may increase treatment efficacy and tolerability therefore relevant 
for effective treatment. We demonstrate how this approach can be validated in the 
treatment of Parkinson’s disease by identifying connectivity patterns that can be used 
as biomarkers for treatment planning and thus refine the traditional approach of DBS 
planning that uses only gray matter landmarks. Finally, we describe how this approach 
could be used in planning DBS treatment of psychiatric disorders.
Keywords: deep brain stimulation, machine learning applied to neuroscience, multimodal imaging, individual 
variability, precision psychiatry
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inTrODUcTiOn
The neuropathology underlying psychiatric disorders is poorly 
defined, and, consequently, psychiatric nosology is mainly 
informed by clinical observation. As a result, psychiatric diag-
noses are likely heterogeneous, multifaceted, and overlapping 
in their etiology and pathophysiology (1). This motivates efforts 
to characterize valid and reliable biological markers of disease 
expression in order to facilitate early identification and novel treat-
ment discovery. Neuroimaging has already had a transformative 
role in psychiatry, as it has established that psychiatric disorders 
are disorder of the brain. Magnetic resonance imaging (MRI) 
methods, and particularly functional MRI (fMRI), diffusion-
weighted, and diffusion tensor imaging (DWI/DTI), have been 
extensively used to assess alterations in brain functional and 
structural organization associated with psychiatric disorders (2, 
3). Findings from the neuroimaging literature have improved the 
characterization of the biological underpinnings of psychiatric 
disorders but have had limited clinical utility, as they are based 
on group-level inferences that cannot be readily applied to single 
individuals (4).
The term “third-generation imaging” collectively describes the 
development of new paradigms in image acquisition and analysis 
that aim to identify brain markers that can improve diagnostic 
assessment and prognostic formulations and lead to personalized 
treatment planning (4). In this article, we highlight the potential 
of multivariate pattern recognition methods to address areas of 
diagnostic and prognostic uncertainty in mood disorders, and 
we then focus on the promise of high-field imaging in leading 
to identification and targeting of patient-specific neural targets.
MUlTiVariaTe PaTTern recOgniTiOn 
MeThODs in PsYchiaTric DisOrDers
The majority of neuroimaging studies in psychiatry use voxel-
based statistics (e.g., general linear model), which are biased 
toward detecting group-level differences that are highly localized 
in space and linear in nature. However, structural and fMRI data 
are inherently multivariate since each imaging dataset contains 
information distributed among the thousands of its constituent 
voxels. Over the last 5 years, there has been increasing interest 
in multivariate pattern recognition methods, as these methods 
can capture potentially useful information embedded in the 
spatial pattern of the data. Multivariate pattern recognition 
can be achieved through several statistical models. Regardless 
of the model, pattern recognition tools rely on computational 
algorithms to discover regularities in the data, which are then 
used to derive rules for inferring individual-level characteriza-
tion (5) (Figure  1). This feature is of translational value, as it 
is aligned with the person-centered nature of clinical practice. 
In psychiatric neuroimaging, multivariate pattern recognition 
methods have been mostly used to classify individuals into 
discreet categories according to diagnostic status (e.g., patients, 
healthy controls), prognosis (e.g., converters, non-converters), or 
treatment response (e.g., treatment responders, non-responders). 
Frequently used classifiers are support vector machines and 
Gaussian process classifiers, which use a supervised approach 
to classification. This means that the algorithm is first trained to 
identify regularities in the neuroimaging data that discriminate 
individuals whose status is predefined. For example, the clas-
sifier is given imaging data from patients and healthy controls 
and is trained to generate a classification rule that discriminates 
the two groups. In the next phase, the test phase, the classifier 
is presented with a dataset from a previously unseen individual 
and uses the classification rule to determine the status of this 
new example. Sensitivity, specificity, and accuracy are the most 
commonly reported measures of classifier performance in terms 
of the accuracy of the classification rule in determining the status 
of previously unseen individual datasets. In the case of binary 
classifiers, for example, involving patients and controls, sensitiv-
ity refers to the proportion of patients (true positives) who are 
correctly identified as patients, whereas specificity measures 
the proportion of controls (true negatives) who are correctly 
identified as controls. The accuracy of the classifier refers to 
the total proportion of patients and controls that are correctly 
classified. Furthermore, permutation testing is also employed to 
determine whether the results of the pattern recognition model 
deviate significantly from chance. In linear classifiers, voxels can 
be visualized on the basis of their contribution to classification 
thus producing discriminative maps (6). The relevant literature 
in psychiatry has recently been summarized in multiple reviews 
that provide a comprehensive account of the progress to date and 
the challenges that still lie ahead (7–10). The field is dominated 
by studies that sought to discriminate healthy individuals from 
patients with either schizophrenia (n = 51) or major depressive 
disorder (MDD) (n =  31) using structural, diffusion-weighted, 
and fMRI data; the reported accuracies of these case–control clas-
sifiers range between 71 and 96% for schizophrenia and between 
61 and 96% for MDD (10).
We focus here on bipolar disorder (BD) where the current 
evidence base is rather limited despite the fact that BD ranks 
among the leading causes of disability worldwide across all age 
groups (11). BD is a mood disorder characterized by episodes of 
depression and mania and executive function impairments. Our 
group (12) and other labs (13–17) have tested the value of struc-
tural MRI data in discriminating patients with BD from healthy 
individuals leading to poor (15) or moderate results (12, 16, 17). 
Investigations using fMRI data from tasks of verbal fluency (18), 
facial affect processing (19–21), auditory oddball detection (22), 
and working memory (23) have been more promising, resulting 
in overall accuracy of approximately 80%. The reported classifi-
cation accuracies do not appear substantially influenced by the 
type of task or the neuroimaging features (connectivity measures 
or whole-brain task-based signal change) used for classification 
(18–23). This evidence demonstrates the potential utility of 
pattern recognition models as a diagnostic aid in BD, although 
it does not address the complexity of diagnostic challenges in 
clinical settings.
It could be argued that neuroimaging-based tools may prove 
more useful in situations where clinical assessment and obser-
vation alone are known to be insufficient. The diagnostic and 
prognostic outcome of first-degree relatives of patients with BD 
presents with several such situations of genuine clinical uncer-
tainty. We therefore tested the hypothesis that neuroimaging, 
FigUre 1 | supervised classification using multivariate pattern recognition models. Classification training and test phase: the classifier in initially trained on 
a set with predefined class labels and the classification rule derived is used to assign class membership to a previously unseen dataset.
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coupled with pattern recognition analyses, might assist in the 
evaluation of individuals at risk of BD by virtue of a positive 
family history for this disorder. Genetic proximity to patients 
remains the most significant predictor of morbidity that is not 
limited to increased risk for BD but includes other adverse 
outcomes, most commonly MDD. The respective morbidity 
risks in first-degree relatives of bipolar patients generally range 
from 4 to 6% for BD and 11 to 18% for MDD (24). There are 
two key areas of clinical uncertainty in assessing first-degree 
relatives of bipolar patients. The first refers to the differential 
diagnosis of BD from MDD in these individuals. Differentiating 
these two disorders is generally challenging (25), because the 
clinical presentation of both disorders is dominated by depres-
sive symptoms (26). There are several demographic and clinical 
features that are more indicative of bipolar depression but, at 
the level of the individual patient, depressive episodes arising 
in the context of BD do not differ substantially from those seen 
in MDD (27–29). Furthermore, depressive episodes generally 
precede the onset of the first manic episode by several years 
(30). It is therefore rather common for individuals with BD 
to present with depression and to be incorrectly diagnosed as 
having MDD. The consequences of misdiagnosis include poten-
tial worsening of the illness course and greater psychosocial 
disability (25). In this scenario, it would be helpful to have a 
diagnostic tool that could differentiate BD from MDD in indi-
viduals with positive family history of bipolarity. The second 
challenge refers to the accurate risk stratification of individuals 
with a positive family history of BD. As discussed first-degree 
relatives of patients, as a group, have a higher risk than the 
general population for affective morbidity (24, 31). However, 
a substantial number of relatives, up to 60%, may remain free 
of psychopathology. Correctly identifying individuals who are 
very unlikely to present with a psychiatric disorder is critical for 
developing a neuroscience-informed framework for targeted 
early intervention.
In order to address these issues, we obtained working memory 
task-related fMRI data from 120 demographically and IQ matched 
participants consisting of 30 patients with BD-type I (15 men and 
15 women, mean age = 34.7 years, SD = 7.7 years), 30 of their 
first-degree relatives diagnosed with MDD (16 men, 15 women, 
mean age = 32.9 years, SD = 9.9 years), 30 psychiatrically healthy 
first-degree relatives (14 men, 16 women, mean age = 35.3 years, 
SD =  5.6  years), and 30 unrelated healthy controls (15 men, 
15 women, mean age =  33.4 years, SD =  11.6 years). Only six 
participants were related to each other. Participants with BD or 
MDD were in symptomatic remission at the time of scanning, 
defined as a total score of <7 in the Hamilton Depression Rating 
Scale and in the Young Mania Rating Scale. Patients with BD were 
prescribed atypical antipsychotics (n = 21), antiepileptics (n = 8), 
and lithium (n = 14), as monotherapy (n = 18) or combination 
therapy (n =  12). Three relatives with MDD were on selective 
serotonin reuptake inhibitors.
Images were acquired using a 1.5-T GE Neuro-optimized Signa 
MR system (General Electric, Milwaukee, WI, USA) fitted with 
40 mT/m high speed gradients. The MRI protocol included a total 
of 180 T2*-weighted MR brain volumes depicting blood–oxygen 
level dependent (BOLD) contrast acquired at each of 36 near-axial 
planes parallel to the inter-commissural plane; repetition time 
(TR) = 3000 ms, echo time (TE) = 40 ms, slice thickness = 3 mm, 
voxel dimensions = 3.75 mm × 3.75 mm × 3.30 mm, interslice 
gap = 0.3 mm, matrix size = 64 × 64, and flip angle = 9°. During 
the same session, a high-resolution, T1-weighted structural image 
was acquired in the axial plane [inversion recovery prepared, 
spoiled gradient-echo sequence; inversion time (TI) = 450 ms, 
TR = 18 ms, TE = 5.1 ms, slice thickness = 1.5 mm, voxel dimen-
sions = 0.9375 mm × 0.9375 mm × 1.5 mm, matrix size 256 × 192, 
field of view (FOV) = 240 mm × 180 mm, flip angle = 20°, and 
number of excitations = 1]. Task-related fMRI data were obtained 
using the typical letter-based 3-back task in a block design with 
the 0-back condition as sensorimotor control. We chose the 
3-back contrast as in our view, and it represents a selection of an 
enriched feature for pattern recognition analysis as individual dif-
ferences in activation patterns are more reliably observed in more 
demanding task conditions (32). The images were realigned, nor-
malized to the Montreal Neurological Institute (MNI) template, 
smoothed (using an 8-mm Gaussian kernel), and analyzed using 
a conventional general linear model. All fMRI data processing 
and analyses were implemented Statistical Parametric Mapping 
FigUre 2 | Discriminative clusters. Clusters discriminating patients with 
bipolar disorder from their relatives with major depressive disorder (red) or 
their healthy relatives (green); PFC, prefrontal cortex.
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(SPM8)1. Performance was evaluated in terms of reaction time to 
target letters and accuracy (% correct responses). Accuracy was 
69.8 (16.7) in patients with BD, 73.4 (17.2) in relatives with MDD, 
88.5 (14.3) in healthy relatives, and 73.2 (12.4) in healthy controls. 
The only significant differences concerned the healthy relatives 
who outperformed all other groups (all p < 0.01). Further details 
of the sample and the paradigm can be found in the original stud-
ies (21, 23, 33–48).
Binary Gaussian process classifiers (49) using whole-brain 
individual beta maps for the contrast of 3-back vs. 0-back were 
implemented in the Pattern Recognition for Neuroimaging 
Toolbox (PRoNTo)2 in order to determine their usefulness in 
differentiating patients with BD (a) from healthy individuals, (b) 
from relatives with MDD, and (c) from psychiatrically healthy 
relatives. Each of these classifiers was trained using a leave-two-
out cross-validation iteration, whereby model is repeatedly refit 
leaving out a pair of observation from each group and then used 
to derive a prediction for the left-out observations. For each trial, 
we thresholded the probabilistic predictions at 0.5 to convert the 
probabilistic predictions to class labels allowing the sensitivity 
and specificity of classification to be computed over all trials. 
The statistical significance of each classifier was determined by 
permutation testing by repeatedly retraining the classifier after 
permuting the class labels (1000 permutations). A p-value for 
classification accuracy was computed by counting the number 
of permutations for which the permuted accuracy was equal or 
greater than the true accuracy (obtained with non-permuted 
labels), then dividing by 1000. Each classifier yields a discrimina-
tion map with the spatial distribution of voxels that contributed 
to the discrimination function.
Patients with BD were discriminated from unrelated healthy 
controls with a sensitivity (true positives for BD) of 84.6%, speci-
ficity (true negatives for unrelated controls) of 92.3%, and overall 
accuracy of 83.5% (p = 0.001). The largest clusters discriminat-
ing patients with BD from unrelated controls were located in 
the prefrontal cortex (encompassing the left inferior, middle, 
and superior frontal gyrus and in the superior parietal lobule). 
This finding is in line with results reported in other samples of 
patients with BD using classifiers based on different activation 
tasks (18–23).
The Gaussian process classifier discriminated patients with BD 
from their MDD relatives with a sensitivity (true positives for 
patients with BD) of 53.9%, specificity (true negative for relatives 
with MDD) of 94.5%, and overall classification accuracy of 73.1% 
(p = 0.001). The largest discriminating clusters were located in 
the left superior frontal gyrus, right middle frontal gyrus, bilater-
ally in the middle/superior frontal gyrus, and the right temporal 
lobe (Figure 2). Previous studies have shown that different task-
based fMRI classifiers can discriminate patients with BD from 
unselected patients with MDD with classification accuracy of 
approximately 80% (10). The present study shows that similar 
classification accuracy can be achieved even when patients have 
family history of BD. Importantly, patients with BD and their 
1 www.fil.ion.ucl.ac.uk/spm/software/spm8/
2 www.mlnl.cs.ucl.ac.uk/pronto/
relatives with MDD could be classified with high specificity. This 
opens the possibility of excluding the BD, with a very high level 
of confidence after a 10-min brain scan, when assessing individu-
als with MDD at high risk for BD by virtue of a positive family 
history. Clinical application will require replication in different 
samples and settings and in more diverse clinical populations. 
Nevertheless, these findings demonstrate the potential value of 
neuroimaging in assisting in situations of clinical uncertainty.
Patients with BD could be differentiated from their healthy 
relatives with a sensitivity (true positives for patients with BD) 
of 72.7%, specificity (true negative for healthy relatives) of 
90.9%, and overall classification accuracy of 81.8% (p = 0.004). 
The largest discriminating clusters were located in the lingual/
inferior occipital gyrus and the cerebellum on the left (Figure 2). 
The high specificity of the classifier denotes that 90% of high-risk 
individuals unlikely to convert to BD will be correctly identified. 
Because of the relatively low sensitivity, some true positives may 
be missed. The ability to provide personalized risk estimates in 
individuals at familial risk for BD is essential in designing tar-
geted and cost-effective intervention services and in preventing 
unnecessary treatment, concern, and self-stigmatization in those 
unlikely to convert to BD. These results are very encouraging and 
could potentially inform early intervention services, where posi-
tive family history is a key criterion of risk and possible service 
inclusion (31). At-risk mental states are “pluripotential” as family 
history of a psychiatric disorder is associated with increased risk 
for multiple adverse health outcomes. Hence, identifying those 
unlikely to become unwell may be a more sensible strategy than 
trying to identify “converters” to a specific diagnosis. The clusters 
contributing to the correct categorization of healthy relatives 
in this study show biological plausibility, as previous reports 
5O’Halloran et al. Neuroimaging Clinical Application
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have shown that the resilient relatives of patients with BD show 
increased cerebral volume (34) and greater occipital connectivity 
(49) when compared to patients or unrelated healthy controls.
The data that we present here demonstrate the promise of 
pattern recognition models, but there are many challenges to 
overcome before these models are ready for widespread clinical 
use. A full review is outside the scope of this article, but key 
challenges involve testing the generalizability of the results in 
different samples and across different research centers. The issue 
of medication contributing to the classifier performance cannot 
be fully accounted or modeled and will require re-evaluation in 
drug-free samples. A further challenge is providing appropriate 
training to clinicians and information to the public to deal with 
the probabilistic nature of machine learning predictions.
An additional challenge relates to individual variability at the 
level of brain organization. The development of methodological 
innovations to improve precision in measuring brain pheno-
types will greatly assist in moving the field forward. In the next 
sections, we describe novel approaches designed to capture 
individual variability thus improving the translational potential 
of neuroimaging.
PrecisiOn MaPPing OF sTrUcTUral 
anD FUncTiOnal cOnnecTiViTY
The increasing availability of high-field MRI scanners, improve-
ments in susceptibility correction methods, and advances in 
sequence developments enable the in  vivo investigation of the 
human brain at higher resolution and higher signal-to-noise ratio 
than ever before. We illustrate the benefits of high-field imaging 
using data obtained with DWI/DTI (50), a technique that yields 
measures of water diffusion within the brain. One DTI-derived 
measure is fractional anisotropy (FA) that reflects the relative 
degree to which water diffusion is not evenly restricted in all 
directions; FA is elevated in areas with high density of white mat-
ter tracts due to diffusion being more restricted perpendicular to 
tracts than along the tracts. Figure 3 provides a visual compari-
son of FA maps (Figure 3, gray scale images) with the preferred 
direction of diffusion (Figure 3, colored lines) derived from a 7-T 
compared to a 3-T diffusion-weighted scan. This demonstrates 
the improvement in the characterization of the anterior limb of 
the internal capsule (ALIC) and of the boundary between white 
matter and cortical gray matter with 7-T compared to 3-T.
A consequence of increased resolution is that inter-individual 
variability in local morphometry and structure–function cor-
respondence becomes more apparent. Individual differences 
exist in cortical folding as well as in the relationship of cortical 
curvature and functional localization (51, 52). However, current 
standard procedures for functional and anatomical analyses rely 
on normalization of individual brains to common templates 
based on stereotaxic coordinates and macro-anatomical land-
marks. These procedures do not optimally take into account 
these individual differences, which can lead to misalignment of 
neuronal activation between subjects (53). As scan resolution 
increases, allowing for incrementally fine-grained localization of 
brain function to cortical gyri and sulci within individual brains, 
the loss of precision due to normalization paradigms becomes 
more pronounced. Here, we introduce the concept of “precision 
mapping,” an approach that addresses this issue by integrating 
multiple imaging modalities in a single-subject-centered analysis 
to identify functionally specialized regions in a way does not 
require normalization to standard templates.
To illustrate the usefulness of precision mapping, we focus on 
the connectivity profiles of the nucleus accumbens (NAc) and 
the ventral prefrontal cortex (vPFC). Precision mapping involves 
the following four steps. First, white matter seeds and gray mat-
ter targets were determined in native space on an anatomical 
T1-weighted scan (Figure 4, step 1). The NAc and the vPFC were 
defined using Freesurfer3 segmentation. For the vPFC, multiple 
Freesurfer regions were combined, and a superior and posterior 
boundary was identified in MNI coordinate space and transformed 
to the individual’s native space. White matter seeds were selected 
in MNI space, based on the white matter anterior to the NAc 
and knowledge from tracer studies (54, 55), and transformed to 
the individual diffusion space. Second, probabilistic tractography 
was performed using probtrackX2 in FSL (56) (Figure 4, step 2). 
Third, the endpoints of the tractography were used to identify 
subregions within the vPFC that is anatomically connected to the 
NAc, and projected onto the Freesurfer cortical surface to include 
the full depth of the cortical ribbon (Figure 4, step 3). Fourth, the 
tractography-determined vPFC subregions and the correspond-
ing subcortical targets were affine transformed to the fMRI space 
and used for functional connectivity analyses (Figure 4, step 4). 
The MNI space is only used for the identification of seed regions 
as a starting point for tractography, but all further processing is 
completely template independent and therefore individual spe-
cific. Thus, the defined network regions can vary in exact location 
and shape depending on the morphology of the tracts and the 
cortical surface within each individual.
There are three critical advantages of precision mapping for 
psychiatric research and treatment development:
 (a) Retention of the individual variation: precision mapping 
does not depend on common neuroanatomical templates 
or standard atlases. All analyses are performed in each 
individual’s native space, and affine transformations are only 
applied to coregister the volumes across the anatomical, dif-
fusion, and functional acquisitions.
 (b) Optimized identification of functionally homologous regions: 
precision mapping defines functionally homologous regions 
by relying on regional anatomical “connectivity fingerprints” 
(57), which closely correspond to regional functional spe-
cialization at very fine-grained scales in the human brain, 
the animal brain, and at the neuronal level in vitro (58–60). 
This approach thus enables the identification of functionally 
homologous regions across individuals, without requiring 
stereotaxic uniformity of functional organization.
 (c) Improved alignment of structural and functional con-
nectivity. Precision mapping allows the identification of 
individual-specific direct anatomical connections between 
3 http://surfer.nmr.mgh.harvard.edu/
FigUre 4 | schematic illustration of the processes involved in precision mapping. Step 1: seeds (red) and targets (vPFC: yellow; nucleus accumbens: 
green) are identified in native space. Step 2: probabilistic tractography is performed. The tract is binarized at 1% of the maximum value (red). Step 3: the segments 
(red) of the vPFC that is connected to the nucleus accumbens are identified and transformed to the cortical surface in order to include the entire depth of the cortex. 
Step 4: the cortical segments and the nucleus accumbens segmentation are transformed to the native functional MRI space, and BOLD time series are extracted to 
perform functional connectivity or dynamic causal modeling (DCM) analysis of the tractography-defined network.
FigUre 3 | Tractography at 3-T compared to 7-T. Tracts connecting the nucleus accumbens (shown in green) to the ventral prefrontal cortex from diffusion-
weighted imaging at 3-T (a) and 7-T (B). Tract probability map >1% of streamlines (red) corrected for distance; primary diffusion direction overlaid on T1-weighted 
image.
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brain regions of interest. This yields a more complete picture 
of the functional interactions between regions compared to 
standard group-based functional connectivity analyses.
The multimodal nature of precision mapping is ideally suited 
to investigate multiple potential causes of network dysfunction 
within and across individual patients. Qualitative inspection 
of the data may be on occasion sufficient to identify unusual 
connectivity segments and can be supplemented by quantitative 
analyses. Given a large enough sample, the extracted metrics of 
functional connectivity, anatomical connectivity, and gray matter 
density may be used to uncover dimensions or different types of 
network dysconnectivity or (dys)function within patient popula-
tions, as well as their variability healthy individuals (Figure 5). 
Precision mapping is a first step on a new route to clinically 
translational neuroimaging that can yield an understanding of 
the nature of brain network pathology in individual patients and 
its variability between patients.
PrecisiOn TargeTing OF  
PaTienT-sPeciFic TargeT neTWOrKs 
FOr TreaTMenT
In neurological disorders, neuroimaging has enabled the success-
ful application of neurosurgical treatments particularly deep brain 
stimulation (DBS). DBS has been approved by the Food and Drug 
Administration (FDA) under a humanitarian device exemption 
for the treatment of movement disorders, such as Parkinson’s 
disease (PD), dystonia, and essential tremor. Although medica-
tions can be remarkably effective at controlling symptoms, DBS 
is the currently the most effective option to control symptoms 
FigUre 5 | (a) Segmentation and tracks and (B) circle plot of connectivity.
FigUre 6 | Fiber tracks from three separate patients with electrodes targeting either the caudal zona incerta (cZi) (a), the subthalamic nucleus 
(sTn) (B), or the globus pallidus interna (gpi) (c). These sagittal views show the fiber tracks that pass through a 3-mm sphere centered on the active electrode 
and may represent fibers of passage most affected by deep brain stimulation (DBS).
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and increase quality of life for patients who are refractory (61, 
62). The improved efficacy of DBS relies on the targeting of the 
circuits involved in PD that connect key subcortical nuclei and 
particularly the globus pallidus interna (GPi), the subthalamic 
nucleus (STN), the caudal zona incerta (cZi), the red nucleus, 
and the substantia nigra (61–64). As such, the success of the 
surgery depends critically on the exact location of the implant in 
relation to these key brain structures. Visualization of the target 
circuitry is commonly achieved by sensitizing the MRI signal to 
the presence of either myelin or iron. Myelin provides contrast 
between gray and white matter, whereas iron (accumulated in 
dopaminergic neurons) provides contrast in the basal ganglia 
and key nuclei of interest in DBS. In conventional DBS, planning 
lead placement is determined in reference to structures deline-
ated by their myelin and iron content. Although relatively high 
success rates are achieved by this method, there are cases in which 
outcomes are suboptimal. A potential explanation for this is that 
current techniques fail to fully characterize the white matter, 
and the tissue is composed of highly myelinated axons. Axons 
are of high relevance to DBS, because they are the most sensitive 
element of the neuron to the stimulation (65–68). The white mat-
ter forms the structural scaffolding of all brain networks. Thus, 
local stimulation of a key white matter tract with DBS can be 
thought of as affecting a network whose edges are composed of 
the fibers of passage around the active electrode. The efficacy of 
DBS may therefore depend on targeting those white matter tracts 
that connect and can therefore modulate activity in multiple key 
multiple regions of disease-related circuits. Direct empirical sup-
port for the role of local stimulation has recently been provided 
in a mouse model of PD using optogenetics and solid-state optics 
(69). In this model, direct selective stimulation of axonal afferents 
to the SNT was associated with therapeutic response. Therefore, 
precision targeting for white matter tracts is important for DBS 
in humans. White matter tractography was introduced to the field 
FigUre 7 | individual patient connectivity plots based on electrode location. Structural connectivity plots from three separate patients with electrodes 
targeting either (a) the caudal zona incerta (cZi), (B) the subthalamic nucleus (STN), or (c) the globus pallidus interna (Gpi).
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of DBS about a decade ago but has yet to be widely adopted as 
shown in a recent review that identified only 15 studies with just 
66 patients (69). Accumulating evidence, however, suggests that 
tractography may prove an essential part of treatment planning 
as the efficacy of DBS is closely associated with the accuracy 
of lead placement in relation to the target brain regions. For 
example, Coenen et al. (70) reported that treatment efficacy in 
patients with PD, essential tremor, and myoclonus dystonia was 
associated with lead placements close to or within the dentato-
rubrothalamic tract (DRT). MDD offers another example where 
variability in DBS outcome has been closely associated with target 
selection; recent evidence suggests that DBS treatment success 
may critically depend on electrode placement in the confluence 
of the uncinate faciculus, forceps, and cingulum bundle (71). 
Hartmann and colleagues (72) used innovative computational 
tractography-based activation models to determine the network 
FigUre 8 | Precision targeting at the individual patient level. The figure 
illustrates the difference between patient-specific connectivity and group 
connectivity to guide targeting for a patient where the caudal zona incerta 
(cZi) has been targeted. The heat map shows where this patient’s 
connectivity is the closest match to the group connectivity average in patients 
having a good treatment response. The actual location of implants is shown 
on the postoperative computerized tomography (CT) scan (blue).
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effects of DBS targets to the NAc and ALIC in patients with obses-
sive compulsive disorder (OCD). They showed that therapeutic 
response in OCD patients show tract selectivity. Similar findings 
in OCD have also been reported by Makris and colleagues (73). 
Identification of the target tract for DBS implantation is further 
complicated by the intricate connectivity profiles of many sub-
cortical DBS targets as is the case with GPi, for example, whose 
connectivity pattern varies along the dorsal to ventral dimension 
with dorsal GPi regions being more connected to motor regions 
(74, 75). Precision targeting is therefore essential for the correct 
identification of the white matter DBS targets.
We focus first on PD because the brain networks involved 
in disease expression are well-characterized and are known to 
involve the striatum, pallidum, and midbrain. Nevertheless, at the 
level of the individual patient, both target network selection and 
optimal electrode placement remain a challenge. The reason for 
this may lie in the unique white matter anatomy of each patient 
and the fact that these deep, centrally located nodes of the net-
work are highly connected “hubs” that serve many functions (76).
In order to explain the efficacy and side effects of DBS, we pro-
pose to establish connectivity profiles associated with three com-
mon targets for the treatment of PD, namely, the cZI, STN, and 
GPi (60–63). To do this, the connectivity profiles 17 PD patients 
who underwent bilateral DBS implantation (5 patients with cZI, 
7 patients with STN, and 5 patients with GPi targets) were com-
puted and compared. All patients provided informed consent in 
accordance with a protocol approved by our institutional review 
board. All patients were imaged preoperatively with MRI under 
general anesthesia on a 3-T GE MRI magnet (Discovery 750, GE 
Healthcare, Waukesha, WI, USA) with a 8-channel receive-only 
head coil (Invivo Corp., Gainesville, FL, USA). The MRI protocol 
included, a T1-weighted sequence for identifying structure and 
segmentation, DWI for white matter characterization, quantita-
tive susceptibility mapping (77) to identify iron-rich deep brain 
nuclei, and contrast-enhanced angiography to identify vessels to 
be avoided during surgical planning. DWI was performed using a 
dual spin echo sequence with 60 independent diffusion-encoding 
directions (b = 1000 s/mm2) and 5 unweighted images, with in-
plane resolution of 2 mm × 2 mm × 3 mm over 61 slices, TR/
TE = 7200/82 ms. T1-weighted imaging was performed using an 
inversion-prepared fast spoiled gradient echo sequence (BRAVO 
FSPGR) with FOV = 24 cm, resolution 1 mm × 1 mm × 1.2 mm 
over 164 slices, TR/TE/TI = 8.1/3.1/450 ms, and flip angle 10°. 
On the day of each surgery (surgeries for left and right implants 
performed on different days), patients were placed in a stereotac-
tic frame (Leksell G Stereotactic Headframe, Elekta, Stockholm, 
Sweden) and underwent computed tomography (CT) imaging 
with 280 mAs, 120 kVP, 0.6 mm × 0.6 mm × 1 mm spatial resolu-
tion, 1000 ms exposure time, on a clinical CT system (Sensation 
Cardiac 64, Siemens, Forcheim, Germany). Postoperative CT 
images were acquired after the removal of the stereotactic frame.
All images were first registered to the first preoperative CT 
scan using FLIRT (FMRIB Linear Image Registration Tool)4 and a 
mutual information cost function. The electrodes were automati-
cally segmented from the second postoperative CT scan (after 
both electrodes were implanted) using software written in-house 
in MATLAB (Mathworks, Natick, MA, USA). The segmentation 
consisted of using a brain mask derived from the structural 
T1-weighted image to mask out regions outside the brain, then 
thresholding at 2000 Houndsfield units to obtain only the elec-
trodes. After segmentation, the right and left leads were separately 
fit to a model of the specific implant (Medtronic 3389 or 3387) to 
obtain segmentations of the implants including each of the four 
electrodes and body of the implant. From the segmentation of the 
electrodes, the centroid of each electrode could be determined. In 
the structural MR dataset, cortical reconstruction and volumetric 
segmentation were performed with Freesurfer. The SPGRE image 
was used as input to Freesurfer. DWI data were corrected for 
Eddy-current distortions using Eddy_correct in FSL and fit to 
the preoperative CT using and affine transform. Fiber tracking 
was performed using the MRtrix package5. Constrained spherical 
deconvolution (78, 79) was performed on preprocessed images 
to obtain fiber orientation distributions. We used a anatomically 
constrained probabilistic tractography algorithm (iFOD2) (80) 
seeded from 3 mm spheres drawn around the centroid of each 
of the four electrodes, for both the left and right implants, to 
determine the connectivity pattern of each seed to cortical and 
4 https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FLIRT
5 https://github.com/MRtrix3/mrtrix3
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subcortical regions using the cortical parcelation and subcortical 
segmentation algorithms (aparc + aseg) in Freesurfer. Figure 6 
shows fiber tracks from three separate patients with electrodes 
targeting either cZI, STN, or GPi. These sagittal views show the 
fiber tracks that pass through the 3-mm sphere centered on the 
active electrode (cathode) and thus can be interpreted as the fibers 
of passage most affected by DBS. The tracks from all three targets 
share some common features as they connect with subcortical 
regions in the brainstem and cerebellum and with cortical regions 
within superior prefrontal cortex. We then averaged connectivity 
matrices from the tracks originating from the active electrode 
separately for each patient group determined by the DBS target 
(cZI, STN, and GPi). We focused on the electrode associated 
with better efficacy and tolerability. Group connectivity plots 
(Figure 7) demonstrate clearly the differences between the three 
targets. Notably, the cZI and STN targets had strong connections 
to the contralateral cerebellar cortex that likely encompasses the 
DRT, as it has a decussation and connects to the contralateral 
dentate nucleus. Strong connections to the ipsilateral superior 
frontal cortex may be partly comprised of fibers that form the 
hyperdirect pathway potentially useful as a target for PD by 
disrupting the synchrony of sensory motor networks (81).
Figure  8 illustrates the benefits of precision targeting at the 
individual patient level for one of the cZI patients. In this patient, 
RMS difference with the average group connectivity from the cZI 
subjects is shown over the preoperative MRI (Figure 8, heat map), 
with the postoperative CT windowed to show only the implant 
(Figure 8, blue). The best match to the group average coincided 
almost exactly with the location of the implant on the right side and 
was approximately 1 mm lateral in the case of the left implant. Note 
that this surgery was planned in the conventional way without con-
sidering DWI. These results show that surgery could be aided by the 
use of DWI-derived connectivity, displayed in this heat map form 
which is easy to import into current surgical-planning software.
Deep brain stimulation for the treatment of psychiatric 
disorders has been gaining more attention since the FDA 
approved DBS (under a Humanitarian Device Exemption) for 
the treatment of OCD in 2009 based on evidence that DBS of 
the ventral internal capsule and ventral striatum may alleviate 
symptoms in intractable cases of this disorder (82, 83). Since 
then, DBS has been extensively studied for the treatment of a 
number of psychiatric disorders, such as MDD and addiction 
(84). Despite some progress, including insights gained from of 
a rich body of animal work on basic mechanisms of DBS (85), 
success in humans has been limited compared to movement dis-
orders. This is primarily because the DBS targets for psychiatric 
disorders are often located in high order associate cortices where 
inter-individual variability is greater than for the phylogenetically 
older subcortical structures targeted in movement disorders. The 
structures targeted in movement disorders, such as the dorsolat-
eral portion of the STN and the posterolateral GPi, have cortical 
connections that are very well conserved from patient to patient. 
By contrast, regions targeted in psychiatric disease, such as the 
NAc, have high inter-individual variability in their connectivity. 
Lehman and colleagues (86) demonstrate this clearly using the 
example of the vPFC, a regions with complex intrinsic functional 
organization and widespread connections with other cortical and 
subcortical regions. Their findings are based on conventional 
FigUre 9 | individual patient tractography based on electrode location in OcD. Tractography from contacts in two patients with obsessive compulsive 
disorder (OCD), Subject 1 (a–c) and Subject 2 (D–F). Fiber tracts are color-coded starting from the most distal: contact 0 (red), contact 1 (yellow), contact 2 (green), 
and contact 4 (blue). Structural T1-weighted MRI is shown in gray, with postoperative computerized tomography (CT) shown in hot colors depicting the skull and the 
electrode. Axial views show the location of the most distal electrodes (a,c) while the sagittal views show the entire electrode including the point it enters the burr 
hole at the top of the image (B,c,e,F).
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tracing techniques and 3D pathway reconstructions of the white 
matter connectomic fingerprint of the vPFC in the primate brain. 
In the preceding section on precision mapping, we discuss the 
same issue and demonstrate individual variability in vmPFC 
connectivity in healthy humans. The topographic organization of 
the efferent and afferent fibers to the vPFC suggests that varia-
tions in DBS electrode placement are likely to affect very different 
cortical and subcortical circuits and that only modulation of a 
selective subset of fibers may have therapeutic effects (72, 73). 
This suggests that in psychiatric disorders the ability to character-
ize individual differences in white matter networks may be even 
more important than in movement disorders. Thus, the patient-
specific, atlas-free approach is applicable and perhaps essential to 
treatment of psychiatric disease with DBS.
Here, we illustrate the use of precision targeting in two 
patients undergoing bilateral DBS of the ALIC for the treatment 
of OCD. Patients gave informed consent to participate in this 
study in accordance with a protocol approved by our institu-
tional review board. Aside from the target selection, we followed 
the same imaging procedures, and data processing procedure 
outlined above for PD patients. OCD patients were implanted 
bilaterally with Medtronic model number 3391. This lead dif-
fered from the models used in the PD patients notably in that the 
electrode spacing is greater (4 vs. 1.5 mm in the 3387 or 0.5 mm 
in the 3389) and the contact size is larger (3 vs. 1.5 mm). Fiber 
tracking from all four contacts in both OCD patients is shown 
in Figure 9. The relative position of the most distal contact to 
the anterior commissure of each implant is depicted in the axial 
slices (Figures 9A,D). In Patient 1, the right implant from was 
placed more posterior than the left implant and both implants 
in Patient 2. Consequently, each contact interacts with a differ-
ent pattern of tracks. In Patient 1, the right implant in all four 
contacts stimulates tracks with similar trajectories toward the 
frontal cortex and contacts 0 and 1 (the two most distal) show 
significant cerebellar components. In Patient 1, the left implant 
is placed within tracts that project to more inferior frontal lobe 
location than those in contact with the right implant. Contact 0 
from the left implant lacks significant projections to the frontal 
lobe and instead projects toward the amygdala and temporal 
lobe, possibly tracing the amygdalofugal tract. In Patient 2, the 
most distal contacts in both leads show the same amygdala-
temporal pattern as the left contact 0 from Patient 1. In Patient 
2, the proximal contacts fan out toward the frontal lobe on 
both sides with the more proximal contacts projecting more 
superiorly. In these two patients, the contacts that showed the 
amygdala–temporal connectivity pattern (Patient 1: left contact 
0; Patient 2: left and right contact 0) showed anxiety responses 
during programing. This suggests that in OCD, amygdalofugal 
involvement during DBS may be predictive of anxiety side 
effects (87).
At present, there is no clear consensus regarding the optimal 
DBS target for OCD (78–80). In the cases, we describe targeting 
the ALIC resulted in individual variability in the fibers passing 
through the DBS leads and these individual differences that may 
be important in surgical planning. Characterizing these connec-
tivity differences and discovering correlates to treatment efficacy 
may point to a connectivity-based target independent from the 
current anatomical references.
cOnclUsiOn anD FUTUre DirecTiOns
Precision medicine utilizes biological and other data to optimize 
and personalize treatment. It firmly places the individual patient 
at the heart of clinical practice and demands that technological 
developments are directed toward tailoring care to individual-
specific variation. In the present paper, we highlight developments 
that aim to harness the power of neuroimaging for precision 
psychiatry. It is clear that the field is still in its infancy, and many 
challenges need to be addressed before the techniques described 
here are ready for deployment in routine clinical practice. Our 
quest for a better understanding of the mechanisms that lead to 
psychiatric disorders is essentially to find biological features that 
are informative in terms of diagnosis, prognosis, and treatment. 
Disruption in brain organization is the most proximal cause of 
psychiatric disorders and neuroimaging provides an invaluable 
tool for identifying and characterizing clinically informative 
features. Developments described here provide a roadmap for 
advancement starting from what is currently achievable.
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